NEW YORK, Jan. 21 - Agencourt Bioscience is set to announce on Tuesday that it will provide genomic services to the Mammalian Gene Collection project of the National Institutes of Health.
Terms of the agreement, funded through a federal contract, call for Agencourt to use its Solid Phase Reversible Immobilization technology to sequence tag mammalian cDNAs and help MGC identify and sequence full-length cDNAs, according to Agencourt.
The project's goal is to identify and sequence a representative full open reading frame clone for each human and mouse gene to be used as a reference for genotyping and haplotyping. It is being carried out by a range of partners, including Clontech and Agencourt.
Although financial details of the deal are not known at this time, Agencourt said that all resources generated by the MGC project will be publicly accessible.
Agencourt, based in Beverly, Mass., provides DNA sequencing, DNA purification, and SNP genotyping services and products to companies in genomics research.